ClinicalTrials.gg
Enrolling by invitationNCT07436689Updated Oct 20, 2026

Long-Term Open-Label Extension Study of Oral Levosimendan

A Phase 3 interventional study of TNX-103 in Pulmonary Hypertension Associated With HFpEF, sponsored by Tenax Therapeutics, Inc.. Enrolling by invitation at 10 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-20.

Sponsored by Tenax Therapeutics, Inc. · Phase 3, Interventional, and Treatment

Updated Oct 20, 2026Eligibility revised1 site addedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
800
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 2,157 studies in Heart Failure with a site in United States — 347 open to participants now, 437 under way, 27 of them phase 3. Heart Failure · United States.

Planned enrollment
171st of 1,601
800 · median 65
Started
2026
with 94 others
Phase 3
147 of 2,157
21 open now
Primary completion
2029-03
later than 362 of 436 live
Registered
2,100th of 2,157
by date

Among the 2,157 studies in Heart Failure with a site in United States, this one is the 171st largest by planned enrollment of the 1,601 interventional ones that give a count, is one of 95 that started in 2026, is one of 147 in phase 3, reaches primary completion later than 362 of the 436 other live ones, and was the 2,100th registered.

Heart Failure

6,334 studies on the registry are indexed under Heart Failure; 1,392 are open to participants now.

Browse Heart Failure studies →

Open to participants now

347 of the 2,157 studies in Heart Failure with a site in United States are open now. Recruiting first, the newest first:

342 more — sign in →

All 347 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 966 Heart Failure studies recruiting now, 689 (71%) set no upper age limit and 89 (9%) stop at 75 or younger; 63 take children under 18; 96 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 2,157 studies in Heart Failure with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study is to provide continued access to treatment with oral levosimendan (TNX-103) and to describe the safety of continued use of TNX-103 in participants with pulmonary hypertension with heart failure with preserved left ventricular ejection fraction (PH-HFpEF) who received TNX-103 in a parent study.

03

Conditions studied

  • Pulmonary Hypertension Associated With HFpEF

Browse trials for

Keywords

  • PH-HFpEF
  • levosimendan
  • HFpEF
  • Heart Failure
  • Pulmonary Hypertension Group 2
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Completed a TNX-103 parent study
  • Investigator confirmation that participant may derive clinical benefit from continued access to TNX-103
  • Requirements related to , , and egg/sperm donation

Exclusion criteria

Exclusion Criteria:

  • Investigator or Sponsor opinion that the participant is unsuitable due to safety, inability to comply, or factors that could compromise study integrity or participant well-being
  • Severe hepatic impairment or cirrhosis ( C) or active untreated or C with evidence of recent infection or viral replication
  • Estimated (eGFR) \< 30 mL/min/1.73 m²
  • Pregnancy or breastfeeding in females
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
800 participants (estimated)

Study arms

  • Experimental
    TNX-103

    Open-label oral levosimendan 1-3mg

    Drug: TNX-103

Interventions

  • Open-label oral levosimendan 1-3mg

06

What researchers measure

Primary outcomes

  1. The incidence (i.e., the percentage of patients who experience at least 1 occurrence) of select AE/SAEs

    The incidence (i.e., the percentage of patients who experience at least 1 occurrence) of select AE/SAEs will be tabulated by system organ class and preferred term.

    Time frame: From enrollment through study completion (up to 3 years)

07

Study locations

10 sites
  • Tenax Investigational Site
    Chicago, Illinois 60611, United States
  • Tenax Investigational Site
    Boston, Massachusetts 02114, United States
  • Tenax Investigational Site
    Minneapolis, Minnesota 55455, United States
  • Tenax Investigational Site
    Rochester, Minnesota 55905, United States
  • Tenax Investigational Site
    St Louis, Missouri 63136, United States
  • Tenax Investigational Site
    Omaha, Nebraska 68198, United States
  • Tenax Investigational Site
    New York, New York 10021, United States
  • Tenax Investigational Site
    Durham, North Carolina 27710, United States
  • Tenax Investigational Site
    Charleston, South Carolina 29425, United States
  • Tenax Investigational Site
    Madison, Wisconsin 53792, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2026 (actual). Primary completion is estimated for Mar 2029, 36 months after the start.

Of 63 industry-sponsored phase 3 interventional studies under Heart Failure, half reached primary completion within 36 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 44. This study's planned 36 months is close to that.

Counting every sponsor, half of 151 studies reached it within 39 months; a quarter within 25 and three quarters within 57.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 20, 2026
First posted
Feb 27, 2026
StartActual
Mar 13, 2026
Primary completionEst.
Mar 2029
CompletionEst.
Mar 2029
Last update
Oct 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
1 site added
Show site
  • Tenax Investigational Site · New York, United States
Oct 20, 2026
Eligibility
Minimum age none→18 Years
Oct 20, 2026
Show all 1 update
  1. Oct 20, 2026
    1 site added
    Show site
    • Tenax Investigational Site · New York, United States
    Eligibility Minimum age none→18 Years
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07436689
Lead sponsor
Tenax Therapeutics, Inc.
Responsible party
Sponsor
First posted
Feb 27, 2026
Start date
Mar 13, 2026
Primary completion
Mar 2029 (estimated)
Completion
Mar 2029 (estimated)
Last update
Oct 20, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: TNX-103

Start the discussion